Common Contracts
2 similar Three-Way Agreement contracts by Nabriva Therapeutics PLC
EX-10.8 6 a18-19043_1ex10d8.htm EX-10.8 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED & RESTATED THREE-WAY AGREEMENT By and Between LABORATORIOS ERN, S.A....Three-Way Agreement • May 5th, 2020
THIS AMENDED AND RESTATED THREE-WAY AGREEMENT (this “Agreement”) is made effective as of 28th July 2016 (the “Effective Date”), by and between Laboratorios ERN, S.A., a Spanish company with a principal place of business at 499 Pedro IV, 08020 Barcelona, Spain, represented by David Solanes López in his capacity as General Manager (“ERN”), Ercros, S.A., a Spanish company with a principal place of business at Paseo del Deleite s/n, 28300 Aranjuez, Spain, represented by Maria del Carmen Cruzado Rodríguez in her capacity as General Manager Pharmaceutical Division (“Ercros”), and Zavante Therapeutics, Inc., a Delaware corporation with a principal place of business at 11750 Sorrento Valley Road, Suite 250, San Diego, CA 92121, represented by Theodore R. Schroeder in his capacity as Chief Executive Officer (“Zavante”) (each individually a “Party” and collectively the “Parties”).
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. AMENDED & RESTATED THREE-WAY AGREEMENT By and Between LABORATORIOS ERN, S.A. and ERCROS, S.A. and ZAVANTE THERAPEUTICS,...Three-Way Agreement • November 6th, 2018 • Nabriva Therapeutics PLC • Pharmaceutical preparations
THIS AMENDED AND RESTATED THREE-WAY AGREEMENT (this “Agreement”) is made effective as of 28th July 2016 (the “Effective Date”), by and between Laboratorios ERN, S.A., a Spanish company with a principal place of business at 499 Pedro IV, 08020 Barcelona, Spain, represented by David Solanes López in his capacity as General Manager (“ERN”), Ercros, S.A., a Spanish company with a principal place of business at Paseo del Deleite s/n, 28300 Aranjuez, Spain, represented by Maria del Carmen Cruzado Rodríguez in her capacity as General Manager Pharmaceutical Division (“Ercros”), and Zavante Therapeutics, Inc., a Delaware corporation with a principal place of business at 11750 Sorrento Valley Road, Suite 250, San Diego, CA 92121, represented by Theodore R. Schroeder in his capacity as Chief Executive Officer (“Zavante”) (each individually a “Party” and collectively the “Parties”).
